bioMerieux (BIM) Stock Forecast & Price Target

Compare

11 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIM Analyst Ratings

Hold

0 Buy

5 Hold

0 Sell

Based on 5 analysts giving stock ratings to

bioMerieux

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIM Stock 12 Month Forecast

Average Price Target

€107.80

▲(11.83% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for bioMerieux in the last 3 months. The average price target is €107.80 with a high forecast of €115.00 and a low forecast of €100.00. The average price target represents a 11.83% change from the last price of €96.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"95":"€95","110":"€110","125":"€125","102.5":"€102.5","117.5":"€117.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€107.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[95,102.5,110,117.5,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.9,98.2923076923077,99.68461538461538,101.07692307692308,102.46923076923078,103.86153846153846,105.25384615384615,106.64615384615385,108.03846153846155,109.43076923076923,110.82307692307693,112.21538461538461,113.6076923076923,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.9,97.73846153846155,98.57692307692308,99.41538461538462,100.25384615384615,101.0923076923077,101.93076923076923,102.76923076923077,103.6076923076923,104.44615384615385,105.28461538461538,106.12307692307692,106.96153846153845,{"y":107.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.9,97.13846153846154,97.37692307692308,97.61538461538461,97.85384615384616,98.0923076923077,98.33076923076923,98.56923076923077,98.8076923076923,99.04615384615384,99.28461538461539,99.52307692307693,99.76153846153846,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":102.736,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.236,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.647,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.647,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.824,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.3,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":96.9,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€115.00

Average Price Target€107.80

Lowest Price Target€100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Charles Pitman CFA

Barclays

€110→€100

Hold

3.73%

Upside

Reiterated

02/24/26

bioMerieux price target lowered to EUR 100 from EUR 110 at BarclaysbioMerieux price target lowered to EUR 100 from EUR 110 at Barclays

Aisyah Noor

Morgan Stanley

€112→€109

Hold

13.07%

Upside

Reiterated

02/02/26

Morgan Stanley Remains a Hold on bioMerieux (0RUG)

Hugo Solvet

Exane BNP Paribas

€100

Hold

3.73%

Upside

Downgraded

01/28/26

bioMerieux downgraded to Neutral from Outperform at BNP ParibasbioMerieux downgraded to Neutral from Outperform at BNP Paribas

Natalia Webster

RBC Capital

€115

Hold

19.29%

Upside

Reiterated

01/23/26

RBC Capital Reaffirms Their Hold Rating on bioMerieux (0RUG)

Anna Ractliffe

Bank of America Securities

€90→€115

Hold

19.29%

Upside

Upgraded

12/12/25

bioMerieux upgraded to Neutral from Underperform at BofAbioMerieux upgraded to Neutral from Underperform at BofA

Kavya Deshpande

UBS

€132→€138

Buy

43.15%

Upside

Reiterated

10/28/25

UBS Sticks to Their Buy Rating for bioMerieux (0RUG)

Maja Pataki

Kepler Capital

€140

Buy

45.23%

Upside

Reiterated

09/08/25

Kepler Capital Sticks to Its Buy Rating for bioMerieux (0RUG)

Anchal Verma

J.P. Morgan

€120.5

Hold

25.00%

Upside

Initiated

08/27/25

bioMerieux (0RUG) Initiated with a Hold at J.P. Morgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Charles Pitman CFA

Barclays

€110→€100

Hold

3.73%

Upside

Reiterated

02/24/26

bioMerieux price target lowered to EUR 100 from EUR 110 at BarclaysbioMerieux price target lowered to EUR 100 from EUR 110 at Barclays

Aisyah Noor

Morgan Stanley

€112→€109

Hold

13.07%

Upside

Reiterated

02/02/26

Morgan Stanley Remains a Hold on bioMerieux (0RUG)

Hugo Solvet

Exane BNP Paribas

€100

Hold

3.73%

Upside

Downgraded

01/28/26

bioMerieux downgraded to Neutral from Outperform at BNP ParibasbioMerieux downgraded to Neutral from Outperform at BNP Paribas

Natalia Webster

RBC Capital

€115

Hold

19.29%

Upside

Reiterated

01/23/26

RBC Capital Reaffirms Their Hold Rating on bioMerieux (0RUG)

Anna Ractliffe

Bank of America Securities

€90→€115

Hold

19.29%

Upside

Upgraded

12/12/25

bioMerieux upgraded to Neutral from Underperform at BofAbioMerieux upgraded to Neutral from Underperform at BofA

Kavya Deshpande

UBS

€132→€138

Buy

43.15%

Upside

Reiterated

10/28/25

UBS Sticks to Their Buy Rating for bioMerieux (0RUG)

Maja Pataki

Kepler Capital

€140

Buy

45.23%

Upside

Reiterated

09/08/25

Kepler Capital Sticks to Its Buy Rating for bioMerieux (0RUG)

Anchal Verma

J.P. Morgan

€120.5

Hold

25.00%

Upside

Initiated

08/27/25

bioMerieux (0RUG) Initiated with a Hold at J.P. Morgan

Stocks with the Highest Top Analyst Consensus in the General Sector

xxx

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering bioMerieux

3 Months

xxx

Success Rate

18/32 ratings generated profit

Average Return

-0.48%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of -0.48% per trade.

1 Year

Maja PatakiKepler Capital

Success Rate

18/32 ratings generated profit

Average Return

+0.74%

reiterated a buy rating 6 months ago

Copying Maja Pataki's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +0.74% per trade.

2 Years

xxx

Success Rate

14/32 ratings generated profit

Average Return

+2.54%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of +2.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIM Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIM has received 0 Buy Ratings, 32 Hold Ratings, and 0 Sell Ratings. BIM average Analyst price target in the past 3 months is 107.80.

Each month's total comprises the sum of three months' worth of ratings.

BIM Financial Forecast

BIM Earnings Forecast

Currently, no earnings data available.

BIM Sales Forecast

Currently, no sales data available.

BIM Stock Forecast FAQ

What is FR:BIM’s average 12-month price target, according to analysts?

Based on analyst ratings, bioMerieux’s 12-month average price target is 107.80.

What is FR:BIM’s upside potential, based on the analysts’ average price target?

bioMerieux has 11.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is bioMerieux a Buy, Sell or Hold?

bioMerieux has a consensus rating of Hold, which is based on 0 buy ratings, 5 hold ratings and 0 sell ratings.

What is bioMerieux’s share price target?

The average share price target for bioMerieux is 107.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €115.00 ,and the lowest forecast is €100.00. The average share price target represents 11.83% Increase from the current price of €96.4.

What do analysts say about bioMerieux?

bioMerieux’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of bioMerieux?

To buy shares of FR:BIM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

bioMerieux (BIM) Stock Forecast & Price Target

BIM Analyst Ratings

BIM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering bioMerieux

BIM Analyst Recommendation Trends

BIM Financial Forecast

BIM Earnings Forecast

BIM Sales Forecast

BIM Stock Forecast FAQ

Detailed List of Analyst Forecasts